Drug or treatment

Bevacizumab clinical trials

• 273Clinical trials
• 58Countries

Newest trials

All recruiting trials (newest 150 of 273)

• Torvutatug samrotecan plus bevacizumab as first-line maintenance in non-HRD advanced epithelial ovarian cancer

  This trial tests whether adding torvu-samrotecan to bevacizumab after standard chemotherapy helps people with non-HRD advanced epithelial ovarian cancer live longer without the cancer worsening compared with bevacizumab alone.

  Recruiting at 4 sites Phase 3 AstraZeneca · Tamarac, Florida and 219 other locations · NCT07851025

• HAIC plus QL1706 and bevacizumab as first-line therapy for unresectable HER2-negative intrahepatic cholangiocarcinoma

  This study tests a liver-directed chemotherapy plus immune therapy and a blood vessel blocker to see if it helps people with unresectable intrahepatic cholangiocarcinoma.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07841574

• Bevacizumab for severe HHT-related nosebleeds

  This study tests whether bevacizumab can help people with hereditary hemorrhagic telangiectasia who have severe nosebleeds.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07828015

• Torvutatug samrotecan with or without bevacizumab as maintenance in platinum-sensitive relapsed epithelial ovarian, fallopian tube, or primary peritoneal cancer

  This study tests torvutatug samrotecan, with or without bevacizumab, to see if it helps people with platinum-sensitive relapsed ovarian, fallopian tube, or primary peritoneal cancer stay cancer-free longer after their last platinum therapy.

  Recruiting at 3 sites Phase 3 AstraZeneca · Anchorage, Alaska and 123 other locations · NCT07816666

• Trastuzumab plus bevacizumab vs bevacizumab alone as first-line maintenance therapy for ovarian cancer

  This trial tests whether adding trastuzumab to bevacizumab maintenance helps people with epithelial ovarian cancer after initial platinum-based therapy.

  Recruiting at 3 sites Phase 3 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Beijing, Beijing Municipality and 2 other locations · NCT07779538

• Raludotatug Deruxtecan With or Without Bevacizumab as First‑Line Maintenance in Advanced Ovarian Cancer

  This trial tests whether maintenance therapy with raludotatug deruxtecan, with or without bevacizumab, helps people with advanced ovarian, fallopian tube, or primary peritoneal cancer live longer without the cancer growing after initial treatment.

  Recruiting at 13 sites Phase 3 Merck Sharp & Dohme LLC · Washington D.C., District of Columbia and 12 other locations · NCT07776691

• Petosemtamab plus chemotherapy vs standard chemo plus cetuximab or bevacizumab in RAS/BRAF WT colorectal cancer

  This phase 3 trial tests whether adding petosemtamab to standard chemotherapy works better than the usual chemo plus cetuximab or bevacizumab for people with recurrent, unresectable, or metastatic colorectal cancer that is KRAS/NRAS/BRAF wild type.

  Recruiting at 5 sites Phase 3 Genmab · Hot Springs, Arkansas and 4 other locations · NCT07775287

• Raludotatug Deruxtecan with or without Bevacizumab for advanced ovarian, peritoneal, or fallopian tube cancer

  This trial tests whether adding raludotatug deruxtecan (R-DXd) to or without bevacizumab helps people with advanced ovarian cancer that progressed after PARP-inhibitor maintenance.

  Recruiting at 7 sites Phase 3 Merck Sharp & Dohme LLC · Fountain Valley, California and 6 other locations · NCT07743164

• Blood biomarkers to predict response to atezolizumab plus bevacizumab in hepatocellular carcinoma

  This study tests whether blood-based biomarkers can predict which patients with advanced liver cancer will respond to first-line atezolizumab plus bevacizumab.

  Recruiting Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT07734857

• Retlirafusp alfa with bevacizumab and chemotherapy (with or without short radiotherapy) for colorectal cancer liver metastases

  This study tests whether adding retlirafusp alfa to bevacizumab and chemotherapy, with or without short-course radiotherapy, can help patients with advanced colorectal cancer that has spread to the liver.

  Recruiting Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07728019

• Bevacizumab, sintilimab, cetuximab and irinotecan in refractory RAS wild-type metastatic colorectal cancer

  This trial tests whether adding sintilimab to a cetuximab and irinotecan backbone, with or without bevacizumab, helps patients with heavily pretreated metastatic colorectal cancer that has RAS wild-type tumors.

  Recruiting Phase 2 Guangdong Provincial People's Hospital · Guangzhou, Guangdong · NCT07722754

• IBI363 with Bevacizumab for Advanced Colorectal Cancer

  This phase 3 trial tests whether giving IBI363 with bevacizumab helps patients with advanced colorectal cancer who have not benefited from standard therapies.

  Recruiting at 2 sites Phase 3 Innovent Biologics (Suzhou) Co. Ltd. · Wuhan, Wuhan and 1 other locations · NCT07722494

• Mo-Rez maintenance therapy in first-line ovarian cancer

  This study tests mocertatug rezetecan (Mo-Rez) alone or with bevacizumab to see if it helps people with newly diagnosed advanced ovarian cancer, compared with bevacizumab alone or no active treatment after initial chemotherapy.

  Recruiting at 12 sites Phase 3 GlaxoSmithKline · Buenos Aires and 11 other locations · NCT07694427

• Mocertatug Rezetecan with Bevacizumab vs Platinum Doublet with Bevacizumab in Platinum-Sensitive Ovarian Cancer

  This trial tests whether mocertatug rezetecan plus bevacizumab helps people with platinum-sensitive ovarian cancer respond better than standard platinum-based therapy plus bevacizumab.

  Recruiting at 9 sites Phase 3 GlaxoSmithKline · Newcastle, New South Wales and 8 other locations · NCT07684612

• HF1K16 with Bevacizumab for recurrent or progressive glioma

  This study tests whether HF1K16 plus Bevacizumab can help adults with recurrent or progressive glioma and whether the combo is safe.

  Recruiting Phase 2 HighField Biopharmaceuticals Corporation · Shanghai, Shanghai Municipality · NCT07678684

• SHR-A1811 plus chemotherapy and bevacizumab as first-line treatment for advanced colorectal cancer

  A first-line treatment test combines SHR-A1811 with chemotherapy and bevacizumab to see if it works better than standard therapy in adults with advanced colorectal cancer.

  Recruiting Phase 3 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Beijing, Beijing Municipality · NCT07676162

• Nodal-Region Sparing Short-Course RT with PD-1 Antibody and Bevacizumab for Rectal Cancer

  This study tests whether a nodal-region sparing short-course radiotherapy followed by chemotherapy plus a PD-1 antibody and bevacizumab is better than the standard short-course radiotherapy with chemotherapy for patients with pMMR/MSS locally advanced rectal cancer.

  Recruiting Phase 2 Sixth Affiliated Hospital, Sun Yat-sen University · Guangzhou, Guangdong · NCT07674732

• TQB2930 plus chemo with or without bevacizumab for HER2-abnormally expressed advanced colorectal cancer

  This trial tests a drug called TQB2930 together with standard chemotherapy, with or without bevacizumab, in adults whose colorectal cancer cannot be removed by surgery and shows HER2 abnormal expression.

  Recruiting at 9 sites Phase 1/2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Beijing, Beijing Municipality and 30 other locations · NCT07653685

• Fine-needle diathermy plus bevacizumab for corneal blood vessel growth

  This study tests whether combining fine-needle diathermy with a bevacizumab injection under the conjunctiva can reduce corneal neovascularization and is safe in adults.

  Recruiting HoChiMinh City Eye Hospital · Ho Chi Minh City, Xuan Hoa · NCT07642960

• Radiotherapy with chemotherapy plus adebrelimab and bevacizumab for TNBC with brain metastases

  This phase II study tests a combination of radiotherapy, cisplatin or carboplatin, adebrelimab, and bevacizumab in adults with triple-negative breast cancer that has spread to the brain.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07638852

• Sac-TMT plus bevacizumab in TNBC with brain metastases

  This phase II, single-arm study tests whether Sac-TMT combined with bevacizumab can help people with triple-negative breast cancer and brain metastases.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07623577

• First-line treatment for biliary tract cancer with iparomlimab, toripalimab, bevacizumab and chemotherapy

  This study tests a combination of iparomlimab and toripalimab with bevacizumab and chemotherapy as the first treatment approach for advanced biliary tract cancer.

  Recruiting Phase 4 Huazhong University of Science and Technology · Wuhan, Hubei · NCT07619235

• HAIC vs. TACE plus sintilimab and bevacizumab for intermediate HCC with high tumor burden

  This trial tests whether FOLFOX-HAIC plus immunotherapy and anti-angiogenic therapy works better than TACE plus the same systemic therapy for adults with intermediate-stage hepatocellular carcinoma with tumors beyond Up-To-Seven criteria.

  Recruiting Phase 3 Sun Yat-sen University · Guangzhou, Guangdong · NCT07594340

• Rina-S with or without bevacizumab after platinum therapy for recurrent platinum-sensitive ovarian cancer

  This trial tests whether Rina-S alone or with bevacizumab works better than the investigator’s choice platinum-based chemotherapy (with or without bevacizumab) for patients with recurrent platinum-sensitive ovarian cancer.

  Recruiting at 12 sites Phase 3 Genmab · Duarte, California and 11 other locations · NCT07564141

• Combining two immunotherapies, a bevacizumab biosimilar, and liver-artery chemotherapy to shrink advanced liver cancer for possible surgery

  This treatment will try a combo of two immune drugs (sintilimab and ipilimumab N01), a bevacizumab biosimilar, and hepatic arterial infusion chemotherapy to shrink unresectable intermediate-to-advanced hepatocellular carcinoma so more patients can become eligible for surgery.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07560488

• Second-line combination treatment for MSS metastatic colorectal cancer

  This trial will try folinic acid plus continuous 5-FU with liposomal irinotecan, sometimes combined with cetuximab or bevacizumab, as a second-line option for adults with MSS metastatic colorectal cancer who progressed on or cannot tolerate oxaliplatin-based therapy.

  Recruiting Phase 2 The First Hospital of Jilin University · Changchun, Jilin · NCT07559760

• Combination therapy with BRII-5395, sintilimab, and bevacizumab in advanced HBV-related hepatocellular carcinoma

  This early-phase study tests BRII-5395 together with two approved cancer drugs to see if it is safe and tolerable in people with advanced HBV-related liver cancer.

  Recruiting Phase 1 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT07557251

• Blood enzyme changes and heart risk after bevacizumab eye injections

  This tests whether repeated bevacizumab eye injections change blood enzymes linked to cardiovascular risk in people aged 55 and older treated for diabetic retinopathy, retinal vein occlusion, or age-related macular degeneration.

  Recruiting Ataturk University · Erzurum, Erzurum · NCT07550777

• Comparing Precem-TcT (with or without bevacizumab) versus trifluridine/tipiracil plus bevacizumab for people with previously treated metastatic colorectal cancer

  This trial will see if Precem-TcT, alone or with bevacizumab, helps people with metastatic colorectal cancer who have already received standard chemotherapy, compared with trifluridine/tipiracil plus bevacizumab.

  Recruiting at 116 sites Phase 3 EMD Serono · San Francisco, California and 115 other locations · NCT07549412

• Short-course radiotherapy plus intensified chemotherapy and targeted therapy with immunotherapy for high-risk rectal cancer

  This trial tests whether adding targeted therapy and a PD-1 inhibitor to a short course of radiotherapy and standard chemotherapy helps high-risk pMMR/MSS rectal cancer patients, compared with the same radiotherapy and chemotherapy alone.

  Recruiting Phase 3 Sixth Affiliated Hospital, Sun Yat-sen University · Guangzhou, Guangdong · NCT07549399

• Telisotuzumab Adizutecan with Bevacizumab vs LONSURF with Bevacizumab in refractory metastatic colorectal cancer

  This study tests whether adding telisotuzumab adizutecan to bevacizumab helps adults with refractory metastatic colorectal cancer more than the standard care of LONSURF plus bevacizumab.

  Recruiting at 88 sites Phase 3 AbbVie · Goodyear, Arizona and 87 other locations · NCT07525206

• Chidamide, sintilimab and bevacizumab as second-line treatment for advanced extrapulmonary neuroendocrine carcinoma

  This trial tests whether the combination of chidamide, sintilimab, and bevacizumab can shrink tumors in adults with advanced extrapulmonary neuroendocrine carcinoma who progressed after first-line therapy.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07518602

• Sacituzumab govitecan with bevacizumab vs standard chemotherapy for recurrent platinum-sensitive ovarian cancer after PARP inhibitor maintenance

  This phase II study tests whether sacituzumab govitecan plus bevacizumab can help people with recurrent platinum-sensitive ovarian cancer, after PARP inhibitor maintenance, more than the usual carboplatin, PLD, and bevacizumab treatment.

  Recruiting at 23 sites Phase 2 National Cancer Institute (NCI) · Fayetteville, Arkansas and 22 other locations · NCT07504588

• Intensified versus conversion therapy for advanced liver cancer after first-line bevacizumab plus sintilimab fails

  This study tests whether adding lenvatinib or switching to regorafenib plus a PD-1 blocker works better and is safe for adults with advanced hepatocellular carcinoma whose cancer progressed after first-line bevacizumab plus sintilimab.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07501351

• SAR445877 with FOLFOX6 and bevacizumab as first-line treatment for MSS metastatic colorectal cancer

  This study tests whether giving SAR445877 together with FOLFOX6 and bevacizumab is safe and tolerable as a first-line treatment for adults with MSS metastatic colorectal cancer.

  Recruiting Phase 1 M.D. Anderson Cancer Center · Houston, Texas · NCT07500298

• AI system to predict response to Atezolizumab-Bevacizumab in unresectable liver cancer

  This study looks at whether an artificial intelligence tool can predict how patients with unresectable hepatocellular carcinoma will respond to atezolizumab-bevacizumab.

  Recruiting First Affiliated Hospital of Wenzhou Medical University · Wenzhou, Zhejiang · NCT07495735

• Targeted FSRT plus bevacizumab versus hippocampus-sparing whole-brain radiation for people with lung adenocarcinoma that has spread to the brain

  This will test whether focused 5-day fractionated stereotactic radiotherapy (FSRT) combined with bevacizumab works better than hippocampus-avoidant whole-brain radiotherapy with a simultaneous boost at controlling brain metastases and protecting memory in adults with lung adenocarcinoma and extensive brain metastases.

  Recruiting at 3 sites Phase 3 Sun Yat-sen University · Chongqing, Chongqing Municipality and 2 other locations · NCT07481786

• AMT-676 combinations for advanced colorectal cancer

  This study tests AMT-676 together with standard chemotherapy and targeted therapies to see if it’s safe and effective for people with unresectable advanced colorectal cancer.

  Recruiting at 8 sites Phase 2 Multitude Therapeutics Inc. · Fuzhou, Fujian and 18 other locations · NCT07474727

• PD-1 versus PD-L1 immunotherapy combined with chemotherapy, with or without bevacizumab, for advanced cervical cancer.

  This trial tests whether giving PD-1 or PD-L1 immunotherapy alongside chemotherapy, with or without bevacizumab, helps adults with metastatic, persistent, or recurrent cervical cancer.

  Recruiting Phase 2/3 N.N. Alexandrov National Cancer Centre · Minsk, Lesnoy · NCT07472153

• RC148 plus chemotherapy as first-line treatment for unresectable or metastatic colorectal cancer

  This study tests RC148 with standard chemotherapy as the first treatment for people with unresectable or metastatic colorectal cancer to see if it helps more than current therapy.

  Recruiting at 19 sites Phase 2/3 RemeGen Co., Ltd. · Beijing, Beijing Municipality and 18 other locations · NCT07462143

• Disitamab vedotin plus bevacizumab for HER2-low metastatic breast cancer after T‑DxD failure

  This study will try disitamab vedotin combined with bevacizumab in adults with HER2‑low metastatic breast cancer whose disease progressed after trastuzumab deruxtecan.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07446452

• Adding pelareorep to FOLFIRI and bevacizumab for second-line RAS‑mutated, MSS metastatic colorectal cancer

  This trial tests whether adding the oncolytic virus pelareorep to standard FOLFIRI plus bevacizumab helps people with RAS‑mutated, microsatellite‑stable metastatic colorectal cancer who progressed after first‑line oxaliplatin therapy.

  Recruiting at 20 sites Phase 2 Oncolytics Biotech · Homewood, Alabama and 19 other locations · NCT07446322

• TACE with sintilimab, bevacizumab, and ipilimumab N01 for advanced liver cancer

  This trial tries a combination of TACE with sintilimab and bevacizumab plus a single dose of ipilimumab N01 given at different times to see if it is safe and helps people with advanced hepatocellular carcinoma whose tumors cannot be removed.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07422753

• PHOENIX: QL1706 plus chemo and bevacizumab in high PD-L1, driver-mutant non-squamous NSCLC

  This trial tests if adding QL1706 to chemotherapy and bevacizumab can help patients with PD-L1 high, driver-mutant non-squamous NSCLC after TKIs.

  Recruiting at 2 sites Phase 2 Guangdong Association of Clinical Trials · Guangzhou, Guangdong,China and 1 other locations · NCT07416058

• First-line trastuzumab-deruxtecan with capecitabine and bevacizumab for HER2-positive metastatic colorectal cancer

  This trial tests whether giving trastuzumab-deruxtecan together with capecitabine and bevacizumab as first treatment helps people with HER2-positive metastatic or unresectable colorectal cancer shrink tumors and respond better.

  Recruiting at 28 sites Phase 2 Gruppo Oncologico del Nord-Ovest · Lyon and 27 other locations · NCT07407465

• Double-dose third-generation EGFR-TKI with bevacizumab and intrathecal chemotherapy for leptomeningeal NSCLC

  This trial will try whether giving a double dose of a third-generation EGFR-TKI together with bevacizumab and spinal (intrathecal) chemotherapy can help people with EGFR-mutant NSCLC whose leptomeningeal metastasis progressed after a standard-dose third-generation EGFR-TKI.

  Recruiting Second Affiliated Hospital of Nanchang University · Nanchang, Jiangxi · NCT07398599

• Intraperitoneal liposomal irinotecan alone or with rmhTNF or bevacizumab for malignant ascites after prior treatments

  This will try an injected form of liposomal irinotecan, alone or with rmhTNF or bevacizumab, in adults with malignant ascites who have not responded to standard therapies.

  Recruiting Phase 1/2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07397819

• Irinotecan plus cetuximab rechallenge versus trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer

  This phase 2 trial tests whether giving irinotecan with cetuximab again helps patients with metastatic colorectal cancer whose disease progressed after standard therapies, compared with the current standard third-line treatment of trifluridine/tipiracil plus bevacizumab, using blood-based molecular profiling to select

  Recruiting at 19 sites Phase 2 Gruppo Oncologico Italia Meridionale · Alessandria and 25 other locations · NCT07381764

• TIPS benefits for people with hepatocellular carcinoma taking Tecentriq (atezolizumab) plus Avastin (bevacizumab) as first-line therapy.

  This study will try to see if placing a TIPS device helps people with advanced or unresectable hepatocellular carcinoma who are starting first-line treatment with Tecentriq plus Avastin.

  Recruiting Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Düsseldorf, North Rhine-Westphalia · NCT07365930

• Neoadjuvant chemotherapy with sintilimab and bevacizumab for triple-negative breast cancer

  This trial will try adding the immunotherapy drug sintilimab and the blood‑vessel blocker bevacizumab to pre-surgery chemotherapy for women with stage II–III triple‑negative breast cancer to see if more tumors disappear completely before surgery.

  Recruiting at 2 sites Phase 2 First Affiliated Hospital of Zhejiang University · Hefei and 1 other locations · NCT07351487

• Short-course radiotherapy plus CAPOX chemotherapy with serplulimab and bevacizumab for mid-low MSS rectal cancer

  This trial will try short-course radiotherapy followed by CAPOX chemotherapy together with serplulimab and bevacizumab before surgery in people with mid-low MSS locally advanced rectal cancer to see if it is safe and shrinks tumors.

  Recruiting Phase 2 First Affiliated Hospital of Wenzhou Medical University · Wenzhou, Zhejiang · NCT07347951

• Liothyronine with BIT chemotherapy for relapsed medulloblastoma in kids and young adults

  This study tests Liothyronine (L-T3) with a BIT chemotherapy regimen in children and young adults whose medulloblastoma has come back or progressed after standard treatment.

  Recruiting at 2 sites Phase 1/2 University of California, San Francisco · San Francisco, California and 2 other locations · NCT07346157

• Sintilimab plus a bevacizumab biosimilar as adjuvant therapy after surgery for ruptured hepatocellular carcinoma

  This trial will test whether giving sintilimab together with a bevacizumab biosimilar after curative surgery can lower recurrence in adults who had a ruptured hepatocellular carcinoma and complete resection.

  Recruiting at 3 sites Phase 2 Ruijin Hospital · Sanming, Fujian and 3 other locations · NCT07331883

• QL1706 with bevacizumab plus RALOX-HAIC for liver cancer with VP3/4 portal vein tumor thrombus

  This trial will test whether giving QL1706 together with bevacizumab and RALOX hepatic arterial infusion chemotherapy helps people with hepatocellular carcinoma and VP3/4 portal vein tumor thrombosis live longer or shrink tumors.

  Recruiting Phase 2 Nanfang Hospital, Southern Medical University · Guangzhou, Guangdong · NCT07327788

• Sintilimab plus bevacizumab biosimilar before surgery for resectable liver cancer

  This trial will test whether giving sintilimab together with a bevacizumab biosimilar before surgery helps people with resectable hepatocellular carcinoma beyond the Milan criteria.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07324824

• Sac-TMT maintenance for people with non-HRD advanced ovarian cancer

  This trial sees if sacituzumab tirumotecan (sac‑TMT), given with or without bevacizumab, can keep cancer from getting worse after surgery and first‑line platinum chemotherapy in people with non‑HRD advanced ovarian cancer.

  Recruiting at 177 sites Phase 3 Merck Sharp & Dohme LLC · Birmingham, Alabama and 176 other locations · NCT07318558

• Disitamab vedotin plus carboplatin and bevacizumab as first-line and maintenance treatment for HER2-expressing, HRD-negative high-risk ovarian cancer

  This study tests whether adding disitamab vedotin to carboplatin and bevacizumab helps people with HER2-expressing, HRD-negative high-risk ovarian cancer as first-line and maintenance treatment.

  Recruiting Phase 2 Jiangsu Cancer Institute & Hospital · Nanjing, Jiangsu and 1 other locations · NCT07311577

• Pumitamig with bevacizumab or temozolomide for adults with recurrent glioblastoma

  This test tries pumitamig, an investigational bispecific immunotherapy, alone or with bevacizumab or temozolomide in adults whose glioblastoma has returned after standard radiotherapy and temozolomide.

  Recruiting at 6 sites Phase 2 BioNTech SE · Beijing and 5 other locations · NCT07297212

• Bevacizumab followed by atezolizumab versus both together for advanced hepatocellular carcinoma with MASLD

  This test will see if giving bevacizumab first and then atezolizumab works better than giving both at the same time for adults with advanced hepatocellular carcinoma and metabolic-associated steatotic liver disease (MASLD).

  Recruiting Phase 2/3 Eastern Hepatobiliary Surgery Hospital · Shanghai, Shanghai Municipality · NCT07285850

• First-line treatment with standard chemotherapy and bevacizumab, with or without INCA33890, for metastatic microsatellite-stable colorectal cancer

  This trial will test whether adding a new drug, INCA33890, to standard chemotherapy and bevacizumab helps people with metastatic microsatellite-stable colorectal cancer respond better or live longer.

  Recruiting at 168 sites Phase 3 Incyte Corporation · Mobile, Alabama and 296 other locations · NCT07284849

• Using fecal microbiota transplantation to try to restore response to atezolizumab and bevacizumab in people with unresectable hepatocellular carcinoma.

  This will try whether giving a fecal microbiota transplant and then restarting atezolizumab plus bevacizumab can restore treatment response in adults with unresectable HCC who progressed early on those drugs.

  Recruiting Phase 2 IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna, BO · NCT07276100

• Trimipramine with atezolizumab and bevacizumab for recurrent glioblastoma

  Researchers will try whether adding the antidepressant trimipramine to the immunotherapy atezolizumab plus bevacizumab helps people with recurrent glioblastoma.

  Recruiting at 7 sites Phase 2 Centre Hospitalier Universitaire Vaudois · Basel, Basel and 6 other locations · NCT07263438

• AK104 plus FOLFIRI with cetuximab or bevacizumab for second-line MSS advanced colorectal cancer

  This trial tests whether adding AK104 to FOLFIRI with either cetuximab or bevacizumab helps people with MSS advanced colorectal cancer who progressed after oxaliplatin-based first-line therapy.

  Recruiting at 2 sites Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang and 1 other locations · NCT07253896

• Carbon ion radiotherapy plus atezolizumab and bevacizumab for advanced hepatocellular carcinoma

  This trial will try adding carbon ion radiotherapy to standard atezolizumab‑bevacizumab treatment for adults with advanced hepatocellular carcinoma to see if it controls tumors better and improves survival.

  Recruiting Phase 2 Yonsei University · Seoul · NCT07246668

• ABT-301 with tislelizumab and bevacizumab for pMMR/non‑MSI‑H advanced or metastatic colorectal cancer

  This trial will test whether adding the oral drug ABT-301 to fixed-dose tislelizumab and bevacizumab is safe and tolerable for adults with pMMR/non‑MSI‑H locally advanced or metastatic colorectal cancer who have had at least two prior systemic therapies.

  Recruiting Phase 1/2 Anbogen Therapeutics, Inc. · Liverpool, New South Wales and 14 other locations · NCT07244705

• Neoadjuvant TACE plus atezolizumab and bevacizumab for resectable high-risk liver cancer

  This study will try combining TACE with atezolizumab and bevacizumab before surgery to see if it shrinks tumors and reduces the chance of recurrence for people with resectable hepatocellular carcinoma who are at high risk of coming back.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality and 3 other locations · NCT07239245

• First-line sequential AG and mFOLFOX with serplulimab and bevacizumab versus AG alone for advanced pancreatic cancer

  This trial will test whether adding serplulimab and bevacizumab to sequential AG and mFOLFOX chemotherapy helps people with untreated advanced pancreatic cancer live longer than standard AG chemotherapy alone.

  Recruiting Phase 3 Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT07235930

• Ivonescimab versus bevacizumab with FOLFOX for first-line metastatic colorectal cancer

  This study tests whether ivonescimab combined with FOLFOX works as well as bevacizumab with FOLFOX for people starting first-line treatment for metastatic colorectal cancer.

  Recruiting at 243 sites Phase 3 Summit Therapeutics · Mobile, Alabama and 242 other locations · NCT07228832

• PF-08634404 plus chemotherapy for adults with metastatic colorectal cancer

  This trial will test whether adding a new drug called PF-08634404 to standard chemotherapy helps adults whose colorectal cancer has spread.

  Recruiting at 343 sites Phase 3 Pfizer · Chandler, Arizona and 371 other locations · NCT07222800

• Pumitamig plus chemotherapy versus bevacizumab plus chemotherapy for untreated metastatic colorectal cancer

  This trial tests whether adding the new drug pumitamig to standard chemotherapy works better than bevacizumab plus chemotherapy for people with previously untreated, unresectable, or metastatic colorectal cancer who do not have MSI‑H/dMMR or BRAF V600E mutations.

  Recruiting at 209 sites Phase 2/3 Bristol-Myers Squibb · Tucson, Arizona and 285 other locations · NCT07221357

• Sacituzumab tirumotecan plus pembrolizumab as first-line maintenance for metastatic cervical cancer

  This trial tests whether adding the antibody-drug conjugate sacituzumab tirumotecan to pembrolizumab (with or without bevacizumab) as maintenance treatment can help people with metastatic cervical cancer live longer or keep the cancer from growing.

  Recruiting at 191 sites Phase 3 Merck Sharp & Dohme LLC · Birmingham, Alabama and 190 other locations · NCT07216703

• Sofetabart Mipitecan (LY4170156) versus standard chemotherapy for platinum-resistant and platinum-sensitive high-grade ovarian, fallopian tube, and primary peritoneal cancer

  This trial tests whether the targeted drug Sofetabart Mipitecan can better shrink tumors or delay progression than standard chemotherapies for people with platinum-resistant or platinum-sensitive high-grade ovarian, fallopian tube, or primary peritoneal cancer.

  Recruiting at 212 sites Phase 3 Eli Lilly and Company · Birmingham, Alabama and 263 other locations · NCT07213804

• HCB101 combined with cetuximab or bevacizumab plus FOLFOX/FOLFIRI for advanced metastatic colorectal cancer

  This trial tries weekly HCB101 infusions together with cetuximab or bevacizumab and FOLFOX or FOLFIRI chemotherapy in adults with advanced or metastatic RAS/BRAF wild-type colorectal cancer who have progressed after prior chemotherapy.

  Recruiting Phase 1/2 Chang Gung Memorial Hospital · Taoyuan · NCT07204574

• Short-course pelvic radiotherapy followed by CAPOX (capecitabine + oxaliplatin) and bevacizumab, with or without PD‑1 immunotherapy, for locally advanced rectal cancer.

  This trial tests whether adding a PD‑1 immunotherapy to short-course radiotherapy followed by CAPOX and bevacizumab helps adults with locally advanced rectal cancer get a higher complete response rate and fewer distant metastases.

  Recruiting Phase 2 Ruijin Hospital · Shanghai · NCT07198165

• Adding bevacizumab to carboplatin, paclitaxel and pembrolizumab for pMMR, TP53‑mutated advanced or recurrent endometrial cancer

  This trial tests whether adding bevacizumab to carboplatin and paclitaxel with pembrolizumab helps people with pMMR, TP53‑mutated advanced or recurrent endometrial cancer live longer without the disease getting worse.

  Recruiting at 308 sites Phase 3 National Cancer Institute (NCI) · Birmingham, Alabama and 308 other locations · NCT07198074

• FOLFOX chemotherapy with atezolizumab and bevacizumab after progression on atezolizumab plus bevacizumab for advanced liver cancer

  This trial will test whether giving FOLFOX chemotherapy together with continued atezolizumab and bevacizumab helps people with advanced hepatocellular carcinoma whose cancer progressed on prior atezolizumab plus bevacizumab.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07192185

• Radiotherapy plus QL1706 and Bevacizumab for unresectable liver cancer

  This study tests whether adding radiotherapy to immunotherapy plus bevacizumab helps people with unresectable hepatocellular carcinoma see better outcomes.

  Recruiting Phase 2 Hebei Medical University Fourth Hospital · Shijiazhuang, Hebei · NCT07179900

• IB-FOLFIRI for BRAF V600E metastatic colorectal cancer

  This trial tests whether adding the immune drugs Iparomlimab and Tuvonralimab to bevacizumab and FOLFIRI helps adults with BRAF V600E metastatic colorectal cancer.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07150247

• Bevacizumab added or not to T-DXd for HER2-low breast cancer with brain metastases

  This trial tests whether adding bevacizumab to trastuzumab deruxtecan helps people with HER2-low breast cancer that has spread to the brain.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07150208

• Anti-PD-1/PD-L1 with bevacizumab and low-dose cyclophosphamide for metastatic NSCLC and cutaneous melanoma after prior checkpoint therapy

  We will try giving anti-PD-1/PD-L1 drugs together with bevacizumab and continuous low-dose cyclophosphamide to people with metastatic NSCLC or cutaneous melanoma whose cancer progressed after prior immune checkpoint treatment.

  Recruiting Phase 2 EuroCityClinic LLC · Saint Petersburg, Sankt-Peterburg · NCT07130032

• TUDCA with camrelizumab and regorafenib for advanced hepatocellular carcinoma after anti‑PD‑1/PD‑L1 plus bevacizumab

  This trial tests whether adding TUDCA to camrelizumab and regorafenib helps people with advanced hepatocellular carcinoma that got worse after anti‑PD‑1/PD‑L1 plus bevacizumab.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07100392

• Bevacizumab plus cisplatin versus cisplatin for malignant serous effusions

  This study tests whether adding bevacizumab to intracavity cisplatin helps people with malignant serous effusions from advanced adenocarcinoma.

  Recruiting Phase 2 Qingdao Central Hospital · Qingdao, Shandong · NCT07090525

• Low-dose trifluridine/tipiracil plus bevacizumab for metastatic colorectal cancer

  This will try a lower-dose trifluridine/tipiracil plus bevacizumab regimen for people with metastatic colorectal cancer who have progressed after at least two prior treatments.

  Recruiting at 2 sites Phase 2 Ruijin Hospital · Sanming and 1 other locations · NCT07085169

• RC48 with bevacizumab or pyrotinib for HER2-positive metastatic breast cancer after T-Dxd failure

  This trial will try RC48 together with either bevacizumab or pyrotinib in adults with HER2-positive metastatic breast cancer whose disease has progressed after trastuzumab deruxtecan (T-Dxd).

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07065435

• HAIC plus iparomlimab or tuvonralimab with bevacizumab, followed by SBRT for advanced liver cancer with portal vein involvement or limited metastases

  This trial will test whether giving hepatic artery infusion chemotherapy with an immune checkpoint antibody (iparomlimab or tuvonralimab) plus bevacizumab, followed by focused stereotactic radiation, helps people with advanced hepatocellular carcinoma that involves the portal vein or has a small number of metastases.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT07062055

• Combining atezolizumab and bevacizumab with Y-90 radioembolization to help people with liver cancer get to transplant

  This trial tests whether adding immunotherapy (atezolizumab plus bevacizumab) to Y-90 radioembolization can help people with hepatocellular carcinoma bridge to or be downstaged for liver transplant.

  Recruiting Phase 4 Icahn School of Medicine at Mount Sinai · New York, New York · NCT07059494

• Fractionated stereotactic radiotherapy plus bevacizumab for multiple brain metastases from lung adenocarcinoma

  This trial tests whether adding bevacizumab to fractionated stereotactic radiotherapy improves intracranial control for people with multiple brain metastases from lung adenocarcinoma.

  Recruiting Phase 3 Sun Yat-sen University · Guangzhou, Guangdong · NCT07058428

• BL-B01D1 plus pembrolizumab, with or without bevacizumab, for recurrent or metastatic cervical and endometrial cancer

  This trial will try a combination of BL-B01D1 and pembrolizumab, with or without bevacizumab, in adults with recurrent or metastatic cervical or endometrial cancer to see if it shrinks tumors or controls the disease.

  Recruiting Phase 2 Sichuan Baili Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT07054567

• PSMA PET/CT for GBM patients on bevacizumab

  This study tests PSMA PET/CT scans in adults with IDH-wildtype glioblastoma who are receiving bevacizumab to see how PSMA expression relates to VEGF in their tumors.

  Recruiting Royal North Shore Hospital · Saint Leonards, New South Wales · NCT07052877

• Lenvatinib plus tislelizumab versus lenvatinib alone for advanced hepatocellular carcinoma after prior PD‑1/PD‑L1 plus bevacizumab

  This trial will test whether adding the immunotherapy tislelizumab to lenvatinib works better than lenvatinib alone for people with advanced liver cancer who progressed after prior PD‑1/PD‑L1 plus bevacizumab treatment.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07047586

• Fractionated liposomal irinotecan with 5‑FU/LV and bevacizumab for second-line advanced colorectal cancer

  This study will test whether giving liposomal irinotecan in split doses together with 5‑FU/LV and bevacizumab helps people with advanced colorectal cancer who need a second-line treatment after oxaliplatin-based therapy.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07047560

• TQB2922 with TAS-102, with or without bevacizumab, for chemo‑resistant RAS/BRAF wild‑type advanced colorectal cancer

  This study will test whether adding the experimental drug TQB2922 to TAS‑102, with or without bevacizumab, helps people with RAS/BRAF wild‑type advanced colorectal cancer that has stopped responding to standard chemotherapy.

  Recruiting Phase 1/2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Hefei, Anhui and 26 other locations · NCT07044908

• Atezolizumab and Bevacizumab before and after surgery for resectable liver cancer

  This study tests whether giving atezolizumab and bevacizumab around surgery can help people with resectable hepatocellular carcinoma see better outcomes.

  Recruiting at 12 sites Phase 2 Fundacion Clinic per a la Recerca Biomédica · Badalona, Barcelona and 11 other locations · NCT07018947

• ctDNA-guided choice of cetuximab versus bevacizumab with trifluridine/tipiracil for RAS/BRAF wild-type metastatic colorectal cancer

  This trial tests whether a ctDNA blood test can help choose cetuximab plus trifluridine/tipiracil versus bevacizumab plus trifluridine/tipiracil for people with RAS/BRAF wild-type metastatic colorectal cancer who have progressed after prior treatments.

  Recruiting Phase 1/2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07012954

• FOLFOX with durvalumab, bevacizumab, and targeted radiation to try to make advanced liver cancer operable

  This will try combining liver-directed FOLFOX chemotherapy, durvalumab, bevacizumab, and focused radiation to see if intermediate or advanced liver cancer can be shrunk enough for surgery.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07012798

• Irpagratinib plus atezolizumab and bevacizumab for advanced hepatocellular carcinoma with FGF19 overexpression

  This trial will test whether adding irpagratinib to atezolizumab and bevacizumab helps people with advanced or unresectable hepatocellular carcinoma whose tumors overexpress FGF19.

  Recruiting Phase 2 Asan Medical Center · Seoul and 2 other locations · NCT07010497

• Short-course radiotherapy plus chemotherapy with optional PD-1 antibody and bevacizumab before surgery for pMMR/MSS locally advanced rectal cancer

  This trial tests whether adding a PD‑1 antibody and bevacizumab to short-course radiotherapy followed by chemotherapy before surgery helps people with pMMR/MSS locally advanced rectal cancer.

  Recruiting Phase 2 Sixth Affiliated Hospital, Sun Yat-sen University · Guangzhou, Guangdong · NCT07005570

• QL1706 and Bevacizumab as first-line treatment for advanced ovarian clear cell carcinoma

  This trial tests whether combining QL1706 with bevacizumab can give adults with newly diagnosed advanced ovarian clear cell carcinoma better outcomes than the standard platinum-based chemotherapy.

  Recruiting Phase 3 Tongji Hospital · Wuhan, Hubei · NCT07002346

• Calderasib plus cetuximab and chemotherapy for KRAS G12C colorectal cancer

  This trial will test whether adding calderasib and cetuximab to mFOLFOX6 helps people with unresectable locally advanced or metastatic colorectal cancer that has a KRAS G12C mutation live longer without their cancer growing.

  Recruiting at 244 sites Phase 3 Merck Sharp & Dohme LLC · Phoenix, Arizona and 244 other locations · NCT06997497

• Comparing two treatments for advanced colorectal cancer

  This study is testing whether a combination of two cancer treatments works better than another combination for people with advanced colorectal cancer that hasn’t responded to other therapies.

  Recruiting Phase 3 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT06992648

• Using FOLFOX-HAIC to treat colorectal liver metastasis that can't be surgically removed

  This study is testing if a new combination of chemotherapy and targeted treatments can help people with colorectal cancer that has spread to the liver and can't be surgically removed, so they can eventually have surgery and live longer.

  Recruiting Phase 2 Tongji Hospital · Wuhan, Hubei · NCT06988852

• BL-B01D1 plus lenvatinib for advanced hepatocellular carcinoma

  This trial tests whether adding BL-B01D1 to lenvatinib helps people with advanced hepatocellular carcinoma shrink tumors or slow disease progression.

  Recruiting Phase 2 Sichuan Baili Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT06986785

• Combination therapy for recurrent triple-negative breast cancer

  This study is testing a combination of two drugs, pembrolizumab and paclitaxel, to see if they can help people with recurrent triple-negative breast cancer who haven't had chemotherapy before.

  Recruiting at 14 sites Phase 2 Japanese Foundation for Cancer Research · Nagoya, Aichi-ken and 13 other locations · NCT06976944

• Testing a new injection treatment for frozen shoulder

  This study is testing a new injection treatment for frozen shoulder to see if it can help reduce pain and improve movement for people with this condition.

  Recruiting Phase 2 Macquarie University, Australia · North Ryde, New South Wales · NCT06976671

• Preventing esophageal varices in liver cancer patients treated with specific medications

  This study is testing whether treating liver cancer patients with specific medications can help prevent the worsening of esophageal varices and reduce the risk of bleeding.

  Recruiting Tanta University · Tanta, Gharbyea · NCT06961526

• Combining node-sparing radiotherapy with chemotherapy and immunotherapy for metastatic colorectal cancer

  This study is testing a new treatment that combines a special type of radiation with chemotherapy and immunotherapy to see if it can help people with metastatic colorectal cancer live longer and feel better.

  Recruiting Phase 2/3 Sixth Affiliated Hospital, Sun Yat-sen University · Guangzhou, Guangdong · NCT06958419

• Fluzoparib with bevacizumab or a low‑carb dietary plan versus fluzoparib alone as first‑line maintenance for HRD‑positive and HRD‑negative advanced ovarian cancer

  This trial tests whether adding bevacizumab or a low‑carb dietary plan to fluzoparib helps women with advanced ovarian cancer, with or without HRD, remain free of cancer longer after first‑line treatment.

  Recruiting at 2 sites Phase 3 Tongji Hospital · Wuhan, Hubei and 1 other locations · NCT06954584

• AK112 plus chemotherapy versus bevacizumab plus chemotherapy for first-line metastatic colorectal cancer

  This tests whether adding AK112 to standard chemotherapy works better than bevacizumab plus chemotherapy as the first treatment for people with metastatic colorectal cancer.

  Recruiting at 2 sites Phase 3 Akeso · Guanzhou, Guangdong and 1 other locations · NCT06951503

• Combining hydroxychloroquine with chemotherapy for advanced colorectal cancer

  This study is testing if adding hydroxychloroquine to standard chemotherapy can help people with advanced colorectal cancer live longer and feel better.

  Recruiting Phase 2 Pavlov First Saint Petersburg State Medical University · Saint Petersburg, Sankt-Peterburg · NCT06949982

• Two-dose ONO-4578 with Opdivo plus mFOLFOX6 and bevacizumab versus standard treatment for advanced PD-L1–positive colorectal cancer

  This trial tests whether adding one of two doses of ONO-4578 to Opdivo, standard chemotherapy (mFOLFOX6), and bevacizumab helps people with PD-L1–positive, non-MSI-H advanced colorectal cancer as their first-line treatment.

  Recruiting at 39 sites Phase 2 Ono Pharmaceutical Co., Ltd. · Phoenix, Arizona and 38 other locations · NCT06948448

• Rilvegostomig plus bevacizumab, with or without tremelimumab, versus atezolizumab plus bevacizumab for advanced liver cancer

  This trial tests whether rilvegostomig combined with bevacizumab, with or without tremelimumab, works better than atezolizumab plus bevacizumab as first-line treatment for people with advanced hepatocellular carcinoma who are not candidates for curative or locoregional therapy.

  Recruiting at 189 sites Phase 3 AstraZeneca · Phoenix, Arizona and 225 other locations · NCT06921785

• Bevacizumab treatment for diabetic eye surgery patients

  This study is testing if giving a medication called bevacizumab right after eye surgery can help people with diabetic eye disease see better and avoid complications.

  Recruiting Christian Ophthalmic Surgery Expedition Network · Querétaro City, Querétaro · NCT06899529

• First-line bevacizumab versus dexamethasone for symptomatic cerebral radiation necrosis after radiation for high-grade glioma or brain metastases.

  This trial will test whether first-line bevacizumab or dexamethasone works better at reducing symptoms in adults with symptomatic cerebral radiation necrosis after radiation for high-grade glioma or brain metastases.

  Recruiting at 5 sites Phase 3 The Netherlands Cancer Institute · Amsterdam and 5 other locations · NCT06888817

• Combination therapy for locally recurrent colorectal cancer

  This study is testing a new combination of medications to see if it can help people with locally recurrent colorectal cancer who have already had surgery for their initial cancer.

  Recruiting Phase 2 Shanghai Changzheng Hospital · Shanghai · NCT06881537

• Nelmastobart plus trifluridine/tipiracil and bevacizumab for metastatic or recurrent colorectal cancer

  This trial tests whether adding nelmastobart to trifluridine/tipiracil and bevacizumab helps adults with metastatic or recurrent colorectal cancer who cannot use oxaliplatin or irinotecan.

  Recruiting Phase 1/2 STCube, Inc. · Seongnam-si, Gyeonggi-do and 4 other locations · NCT06873763

• Combining HAIC with Sintilimab and Bevacizumab for Advanced Liver Cancer

  This study is testing if a new combination of chemotherapy and two other drugs can help people with advanced liver cancer feel better compared to using just the two drugs alone.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06860490

• Combining TAS-102 and Bevacizumab with Local Treatment for Advanced Colorectal Cancer

  This study is testing a new combination of medications and local treatment for patients with advanced colorectal cancer who didn't get better with their first treatment to see if it works better than the usual second-line therapy.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06856187

• Comparing Aflibercept and Bevacizumab for Treating Diabetic Maculopathy

  This study is testing whether two eye injections, aflibercept and bevacizumab, can help improve vision in people over 40 with type 2 diabetes and certain vision problems.

  Recruiting Phase 4 Al-Mustansiriyah University · Baghdad · NCT06850571

• Comparing niraparib and bevacizumab for ovarian cancer maintenance therapy

  This study is trying to see if a maintenance treatment with niraparib works better than bevacizumab for women with advanced ovarian cancer who have already had chemotherapy.

  Recruiting Centre Hospitalier Universitaire de Nīmes · Nîmes, Occitanie · NCT06827353

• Evaluating a new treatment for recurrent ovarian cancer

  This study is testing a new treatment for women with recurrent ovarian cancer to see if it helps them live longer and feel better compared to standard care.

  Recruiting at 201 sites Phase 3 Merck Sharp & Dohme LLC · Birmingham, Alabama and 201 other locations · NCT06824467

• Stereotactic body radiotherapy with atezolizumab and bevacizumab for HCC with major portal vein thrombosis

  This test tries adding SBRT to atezolizumab plus bevacizumab to see if it helps people with HCC and major portal vein thrombosis who have not progressed after two cycles of systemic therapy.

  Recruiting at 2 sites Phase 2 Chinese University of Hong Kong · Hong Kong and 1 other locations · NCT06823375

• Evaluating a new treatment for metastatic colorectal cancer

  This study is testing a new drug combined with standard chemotherapy to see if it helps adults with metastatic colorectal cancer feel better and improve their condition.

  Recruiting at 82 sites Phase 2 AbbVie · Duarte, California and 81 other locations · NCT06820463

• Preventive endoscopic banding for high-risk esophageal varices in people with hepatocellular carcinoma starting atezolizumab plus bevacizumab

  This study will test whether doing preventive endoscopic banding of high-risk esophageal varices can reduce bleeding in people with hepatocellular carcinoma who are starting atezolizumab plus bevacizumab.

  Recruiting Phase 2 Asan Medical Center · Seoul, Song-pa · NCT06819566

• Combining Trastuzumab Deruxtecan with Bevacizumab for Ovarian Cancer Treatment

  This study is testing if combining two drugs, Trastuzumab Deruxtecan and Bevacizumab, can help people with advanced ovarian cancer feel better compared to using Bevacizumab alone.

  Recruiting at 232 sites Phase 3 Daiichi Sankyo · Burbank, California and 231 other locations · NCT06819007

• Elovie (bevacizumab biosimilar) for metastatic colorectal cancer in Brazil

  This project will see if the biosimilar bevacizumab Elovie works well and is safe for adults in Brazil with unresectable stage IV metastatic colorectal cancer receiving first-line therapy.

  Recruiting at 14 sites Libbs Farmacêutica LTDA · Vitória, Espírito Santo and 13 other locations · NCT06808685

• Evaluating Sintilimab and Bevacizumab for Rectal Cancer Treatment

  This study is testing if a new combination of two drugs, sintilimab and bevacizumab, can improve treatment outcomes for people with rectal cancer who have had different previous therapies.

  Recruiting Phase 2 Xijing Hospital of Digestive Diseases · Xi'an, Shaanxi · NCT06808412

• Real-life experience with immunotherapy for liver cancer treatment

  This study is testing new combinations of immunotherapy treatments for liver cancer to see how well they work and how safe they are for patients.

  Recruiting at 16 sites IRCCS Azienda Ospedaliero-Universitaria di Bologna · Torrette, AN and 23 other locations · NCT06806579

• Using irinotecan liposomes with bevacizumab to treat recurrent glioma

  This study is testing if a new combination of irinotecan liposomes and bevacizumab can help people with recurrent brain glioma feel better and live longer after their first treatment didn’t work.

  Recruiting Phase 2 The Central Hospital of Lishui City · Lishui, Zhejiang · NCT06801730

• Fecal transplant plus QL1706, bevacizumab, and XELOX as first-line treatment for advanced MSS colon cancer with liver metastases

  This trial will test whether giving a fecal microbiota transplant before combined QL1706, bevacizumab, and XELOX chemotherapy helps adults with untreated advanced MSS colon cancer that has spread to the liver.

  Recruiting Phase 2 Changzhou No.2 People's Hospital · Changzhou · NCT06801665

• Using cadonilimab with bevacizumab and docetaxel for advanced non-small cell lung cancer

  This study is testing a new combination of treatments, including cadonilimab, bevacizumab, and docetaxel, to see if it can help people with advanced non-small cell lung cancer who haven't had success with other therapies.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT06793813

• Treatment for PD-L1-positive metastatic triple-negative breast cancer

  This study is testing a new treatment plan that combines two drugs after initial therapy to see if it helps people with PD-L1-positive metastatic triple-negative breast cancer live longer without their cancer getting worse.

  Recruiting Phase 2 Japan Breast Cancer Research Group · Koto-ku, 3-8-31, Tokyo · NCT06793553

• Combination therapy for advanced colorectal cancer

  This study is testing a new combination treatment for people with advanced colorectal cancer to see if it can help them respond better to therapy and live longer compared to a standard treatment.

  Recruiting Phase 3 Sixth Affiliated Hospital, Sun Yat-sen University · Guangzhou, Guangdong · NCT06791512

• Combination therapy for hepatocellular carcinoma using atezolizumab, bevacizumab, and memantine

  This study is testing a new combination of three medications to see if it can help people with advanced liver cancer feel better and improve their quality of life.

  Recruiting at 2 sites Phase 2 Inova Health Care Services · Fairfax, Virginia and 1 other locations · NCT06789757

• QL1706 combined with chemotherapy for treating advanced triple negative breast cancer

  This study is testing a new treatment combining QL1706 with chemotherapy to see if it helps women with advanced triple negative breast cancer feel better compared to standard options.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06786026

• Combination treatment for advanced pancreatic cancer

  This study is testing a new combination of treatments for advanced pancreatic cancer to see if it works better than another option for patients who haven't had success with their first treatment.

  Recruiting Phase 1/2 Chinese PLA General Hospital · Beijing and 1 other locations · NCT06782685

• ORIENT-31 plus targeted SBRT for EGFR‑mutant metastatic lung cancer after third‑generation EGFR‑TKI

  This study will test whether adding targeted stereotactic radiotherapy (SBRT) to the ORIENT-31 drug combination helps people with EGFR‑mutant metastatic non‑small cell lung cancer whose disease progressed after first‑line third‑generation EGFR‑TKIs.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06775743

• Combining adebrelimab with chemotherapy for lung cancer treatment

  This study is testing if adding adebrelimab to chemotherapy helps patients with early-stage lung cancer feel better and have better treatment outcomes before surgery.

  Recruiting Phase 2 The First Affiliated Hospital of Guangzhou Medical University · Guangzhou · NCT06775275

• Oral trifluridine/tipiracil with bevacizumab and sintilimab, with or without targeted radiation, for advanced MSS/pMMR colorectal cancer after two or more prior treatments

  This trial will try oral trifluridine/tipiracil combined with bevacizumab and sintilimab, with or without focused radiation, in people with advanced MSS/pMMR colorectal cancer who have progressed after at least two prior therapies.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT06764680

• Combining Befotertinib with Bevacizumab or Chemotherapy for Lung Cancer Treatment

  This study is testing if a new lung cancer treatment combining befotertinib with either bevacizumab or chemotherapy can help patients with early-stage cancer that has an EGFR mutation feel better before surgery.

  Recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, Shanghai Municipality · NCT06755684

• Comparing Amivantamab with FOLFIRI to Cetuximab/Bevacizumab with FOLFIRI for Colorectal Cancer

  This study is testing if a new treatment combining amivantamab with FOLFIRI can help people with certain types of colorectal cancer live longer and feel better compared to the standard treatment with cetuximab or bevacizumab plus FOLFIRI.

  Recruiting at 235 sites Phase 3 Janssen Research & Development, LLC · Chandler, Arizona and 250 other locations · NCT06750094

• Combination treatment for advanced lung cancer with HER2 mutations

  This study is testing a new combination of treatments for people with advanced lung cancer that has HER2 mutations to see if it helps them live longer and feel better.

  Recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai, China · Shanghai · NCT06749860

• Using Bevacizumab before surgery for high-grade brain gliomas

  This study is testing if giving a drug called bevacizumab before surgery can help people with high-grade brain tumors have better outcomes.

  Recruiting The First Affiliated Hospital of Zhengzhou University · Zhengzhou, Henan · NCT06747728

• Combining PD-L1 antibody and Bevacizumab with chemotherapy for advanced liver cancer

  This study is testing a new combination of treatments for people with advanced liver cancer to see if it can help them live longer and feel better.

  Recruiting Phase 2 West China Hospital · Chengdu, Sichuan · NCT06742424

• Combination treatment for advanced liver cancer

  This study is testing a new combination of treatments for people with advanced liver cancer to see if it can help them respond better and live longer.

  Recruiting at 3 sites Phase 2 Sun Yat-sen University · Lanzhou, Gansu and 2 other locations · NCT06737913

• Fluzoparib with or without Bevacizumab for treating advanced ovarian cancer

  This study is testing whether a new drug called Fluzoparib, alone or with another drug called Bevacizumab, can help people with advanced ovarian cancer caused by BRCA1/2 mutations do better than standard chemotherapy.

  Recruiting Phase 2 Qilu Hospital of Shandong University · Jinan, Shandong · NCT06735326

• Combination treatment for metastatic colorectal cancer patients

  This study is testing if adding Atezolizumab to the usual treatment for patients with advanced colorectal cancer can help them live longer without their cancer getting worse.

  Recruiting at 24 sites Phase 3 Gruppo Oncologico del Nord-Ovest · Brescia, BS and 23 other locations · NCT06733038

• Combining radiotherapy and immunotherapy for advanced liver cancer before transplant

  This study is testing if combining radiation therapy with immunotherapy can help people with advanced liver cancer get better and qualify for a liver transplant.

  Recruiting Phase 1/2 University Health Network, Toronto · London, Ontario and 1 other locations · NCT06725121

• Combining SHR-A1811, Pyrotinib, and Bevacizumab for Advanced Breast Cancer with Brain Metastasis

  This study is testing a new combination of three drugs to see if it can help people with advanced breast cancer that has spread to the brain feel better and improve their treatment outcomes.

  Recruiting Phase 1/2 Fudan University · Shanghai, Shanghai Municipality · NCT06718933

• Combining IBI363 with Bevacizumab or Furuitinib for Advanced Colorectal Cancer

  This study is testing if a new drug called IBI363, when combined with either Bevacizumab or Furuitinib, can help adults with advanced colorectal cancer who haven't responded to standard treatments.

  Recruiting Phase 1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT06717880

• New treatment for advanced gastric cancer using TAS-102, bevacizumab, and camrelizumab

  This study is testing a new combination of medications for people with advanced stomach cancer who haven't had success with other treatments to see if it can help them.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT06711471

Showing recruiting studies first, then the newest. Describe your situation to find the ones that fit you.

Quick answers

How many clinical trials of Bevacizumab are recruiting right now?

273, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 58 countries. The most sites are in China (155 trials), United States (63 trials), South Korea (33 trials), Italy (31 trials), France (31 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 140, Phase 3: 59, Phase 1/2: 23, Phase 1: 12. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →